Abstract library

2016 results for "tumor recurrence".
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#1265 Prognostic Factors for Recurrence of Sporadic Pancreatic Neuroendocrine Tumors After Surgical Resection
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare neoplasms with heterogeneous presentation. The diagnosis of malignancy is often difficult, and then further studies may contribute to improve prognosis criteria.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: PhD Estela Regina Ramos Figueira
#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors
Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Valentina Andreasi
#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov
#421 Pelvic Carcinoid Tumor Recurrence Treated by Laparosocopic Ultrasonography Guided Laparoscopic Resection
Introduction: Minute retroperitoneal carcinoid tumor recurrences may be difficult to locate during surgery. A laparoscopic approach to re-resection is further hampered by the lack of tactile sense. Laparoscopic Ultrasonography (LUS) is a minimally invasive method which may compensate for the lack of palpation during laparoscopic surgery, and LUS allows for an evaluation of lesions beneath the visible surfaces. LUS is used in the pretherapeutic staging of upper GI tract cancer, and LUS can identify - and if necessary also biopsy - lesions less than 10 mm in diameter.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Henning O Nielsen
Authors: Nielsen H O, Mortensen M B, ...
#1674 Meta-Analysis of Recurrence after Curative Surgery of Pancreatic Neuroendocrine Tumors.
Introduction: Follow-up after curative surgery for pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence, however reliable recurrence rates are difficult to deduct from literature. Without this knowledge, appropriate follow-up regimens and indications for adjuvant treatment remain unclear.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.
Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone